APO Research
Talk to an analyst

APO RESEARCH · REPORT

Intravenous Immunoglobulin(IVIg) Therapy

Compare research editions
View pricing & licenses

Selected research

Industry Research

Intravenous Immunoglobulin(IVIg) Therapy Industry Research Report 2026

29 December 2025142 pages

Choose your research edition.

Industry ResearchIntravenous Immunoglobulin(IVIg) Therapy Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Intravenous Immunoglobulin(IVIg) Therapy Industry Growth and Trends Forecast to 2032127 pages · $3,450 USDMarket StructureGlobal Intravenous Immunoglobulin(IVIg) Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intravenous Immunoglobulin(IVIg) Therapy Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Intravenous Immunoglobulin(IVIg) Therapy Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Intravenous Immunoglobulin(IVIg) Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Intravenous Immunoglobulin(IVIg) Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Intravenous Immunoglobulin(IVIg) Therapy is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Intravenous Immunoglobulin(IVIg) Therapy is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Intravenous Immunoglobulin(IVIg) Therapy include TEIJIN LIMITED, Baxter, Biotest, Boya-Bio, CNBG, CSL Plasma, Grifols, Kamada and Kedrion, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Intravenous Immunoglobulin(IVIg) Therapy market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Intravenous Immunoglobulin(IVIg) Therapy Market by Company

TEIJIN LIMITED

Baxter

Biotest

Boya-Bio

CNBG

CSL Plasma

Grifols

Kamada

Kedrion

LFB Group

Nanyue Biopharming

Octapharma

Sinopharm

Beijing Tiantan Biological Products

Guangdong Shuagnlin Bio-pharmacy

Hualan Bio

Shanghai RAAS

Weiguang Biological

Taibang Biologic Group

Takeda

Intravenous Immunoglobulin(IVIg) Therapy Segment by Type

5g/100ml

2.5g/50ml

1g/20ml

10g/200ml

1.25g/25ml

Others

Intravenous Immunoglobulin(IVIg) Therapy Segment by Application

Autoimmune Disease

Immunodeficiency

Acute Infection

Others

Intravenous Immunoglobulin(IVIg) Therapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous Immunoglobulin(IVIg) Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intravenous Immunoglobulin(IVIg) Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous Immunoglobulin(IVIg) Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Intravenous Immunoglobulin(IVIg) Therapy manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Intravenous Immunoglobulin(IVIg) Therapy by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Intravenous Immunoglobulin(IVIg) Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Intravenous Immunoglobulin(IVIg) Therapy Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Manufacturers (2021-2026) Table 8. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue of Manufacturers (2021-2026) Table 9. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Intravenous Immunoglobulin(IVIg) Therapy Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Intravenous Immunoglobulin(IVIg) Therapy Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Intravenous Immunoglobulin(IVIg) Therapy, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Intravenous Immunoglobulin(IVIg) Therapy, Product Type & Application Table 14. Global Intravenous Immunoglobulin(IVIg) Therapy Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Intravenous Immunoglobulin(IVIg) Therapy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. TEIJIN LIMITED Company Information Table 19. TEIJIN LIMITED Business Overview Table 20. TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 22. TEIJIN LIMITED Recent Developments Table 23. Baxter Company Information Table 24. Baxter Business Overview Table 25. Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 27. Baxter Recent Developments Table 28. Biotest Company Information Table 29. Biotest Business Overview Table 30. Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 32. Biotest Recent Developments Table 33. Boya-Bio Company Information Table 34. Boya-Bio Business Overview Table 35. Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 37. Boya-Bio Recent Developments Table 38. CNBG Company Information Table 39. CNBG Business Overview Table 40. CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 42. CNBG Recent Developments Table 43. CSL Plasma Company Information Table 44. CSL Plasma Business Overview Table 45. CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 47. CSL Plasma Recent Developments Table 48. Grifols Company Information Table 49. Grifols Business Overview Table 50. Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 52. Grifols Recent Developments Table 53. Kamada Company Information Table 54. Kamada Business Overview Table 55. Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 57. Kamada Recent Developments Table 58. Kedrion Company Information Table 59. Kedrion Business Overview Table 60. Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 62. Kedrion Recent Developments Table 63. LFB Group Company Information Table 64. LFB Group Business Overview Table 65. LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 67. LFB Group Recent Developments Table 68. Nanyue Biopharming Company Information Table 69. Nanyue Biopharming Business Overview Table 70. Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 72. Nanyue Biopharming Recent Developments Table 73. Octapharma Company Information Table 74. Octapharma Business Overview Table 75. Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 77. Octapharma Recent Developments Table 78. Sinopharm Company Information Table 79. Sinopharm Business Overview Table 80. Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 82. Sinopharm Recent Developments Table 83. Beijing Tiantan Biological Products Company Information Table 84. Beijing Tiantan Biological Products Business Overview Table 85. Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 87. Beijing Tiantan Biological Products Recent Developments Table 88. Guangdong Shuagnlin Bio-pharmacy Company Information Table 89. Guangdong Shuagnlin Bio-pharmacy Business Overview Table 90. Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 92. Guangdong Shuagnlin Bio-pharmacy Recent Developments Table 93. Hualan Bio Company Information Table 94. Hualan Bio Business Overview Table 95. Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 97. Hualan Bio Recent Developments Table 98. Shanghai RAAS Company Information Table 99. Shanghai RAAS Business Overview Table 100. Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 102. Shanghai RAAS Recent Developments Table 103. Weiguang Biological Company Information Table 104. Weiguang Biological Business Overview Table 105. Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 107. Weiguang Biological Recent Developments Table 108. Taibang Biologic Group Company Information Table 109. Taibang Biologic Group Business Overview Table 110. Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 112. Taibang Biologic Group Recent Developments Table 113. Takeda Company Information Table 114. Takeda Business Overview Table 115. Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio Table 117. Takeda Recent Developments Table 118. Global Intravenous Immunoglobulin(IVIg) Therapy Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 119. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2021-2026) & (K Units) Table 120. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Region (2021-2026) Table 121. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region (2027-2032) & (K Units) Table 122. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Region (2027-2032) Table 123. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2021-2026) & (US$ Million) Table 124. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Region (2021-2026) Table 125. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region (2027-2032) & (US$ Million) Table 126. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Region (2027-2032) Table 127. North America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 129. North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 130. North America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2026) & (US$ Million) Table 131. North America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2027-2032) & (US$ Million) Table 132. Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 134. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 135. Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2026) & (US$ Million) Table 136. Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2027-2032) & (US$ Million) Table 137. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 139. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 140. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2026) & (US$ Million) Table 141. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2027-2032) & (US$ Million) Table 142. South America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. South America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 144. South America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 145. South America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2026) & (US$ Million) Table 146. South America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 148. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2026) & (K Units) Table 149. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2027-2032) & (K Units) Table 150. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2026) & (US$ Million) Table 151. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2027-2032) & (US$ Million) Table 152. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021-2026) & (K Units) Table 153. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2027-2032) & (K Units) Table 154. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2021-2026) Table 155. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2027-2032) Table 156. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2021-2026) & (US$ Million) Table 157. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2027-2032) & (US$ Million) Table 158. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2021-2026) Table 159. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2027-2032) Table 160. Global Intravenous Immunoglobulin(IVIg) Therapy Price by Type (2021-2026) & (US$/Unit) Table 161. Global Intravenous Immunoglobulin(IVIg) Therapy Price by Type (2027-2032) & (US$/Unit) Table 162. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021-2026) & (K Units) Table 163. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2027-2032) & (K Units) Table 164. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2021-2026) Table 165. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2027-2032) Table 166. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2021-2026) & (US$ Million) Table 167. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2027-2032) & (US$ Million) Table 168. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2021-2026) Table 169. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2027-2032) Table 170. Global Intravenous Immunoglobulin(IVIg) Therapy Price by Application (2021-2026) & (US$/Unit) Table 171. Global Intravenous Immunoglobulin(IVIg) Therapy Price by Application (2027-2032) & (US$/Unit) Table 172. Key Raw Materials Table 173. Raw Materials Key Suppliers Table 174. Intravenous Immunoglobulin(IVIg) Therapy Distributors List Table 175. Intravenous Immunoglobulin(IVIg) Therapy Customers List Table 176. Intravenous Immunoglobulin(IVIg) Therapy Industry Trends Table 177. Intravenous Immunoglobulin(IVIg) Therapy Industry Drivers Table 178. Intravenous Immunoglobulin(IVIg) Therapy Industry Restraints Table 179. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Intravenous Immunoglobulin(IVIg) Therapy Product Image Figure 5. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Intravenous Immunoglobulin(IVIg) Therapy Market Size (2021-2032) & (US$ Million) Figure 7. Global Intravenous Immunoglobulin(IVIg) Therapy Sales (2021-2032) & (K Units) Figure 8. Global Intravenous Immunoglobulin(IVIg) Therapy Average Price (US$/Unit) & (2021-2032) Figure 9. 5g/100ml Product Image Figure 10. 2.5g/50ml Product Image Figure 11. 1g/20ml Product Image Figure 12. 10g/200ml Product Image Figure 13. 1.25g/25ml Product Image Figure 14. Others Product Image Figure 15. Autoimmune Disease Product Image Figure 16. Immunodeficiency Product Image Figure 17. Acute Infection Product Image Figure 18. Others Product Image Figure 19. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Intravenous Immunoglobulin(IVIg) Therapy, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Intravenous Immunoglobulin(IVIg) Therapy Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Intravenous Immunoglobulin(IVIg) Therapy Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region in 2025 Figure 25. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region in 2025 Figure 26. North America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country in 2025 Figure 27. North America Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 28. North America Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Country (2021-2032) Figure 29. United States Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Europe Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country in 2025 Figure 32. Europe Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 33. Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Country (2021-2032) Figure 34. Germany Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. France Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. U.K. Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Italy Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Netherlands Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country in 2025 Figure 40. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 41. Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Country (2021-2032) Figure 42. China Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Japan Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. South Korea Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. India Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Australia Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. China Taiwan Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country in 2025 Figure 51. South America Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 52. South America Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Country (2021-2032) Figure 53. Mexico Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Brazil Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country in 2025 Figure 57. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Country (2021-2032) Figure 59. Turkey Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE Intravenous Immunoglobulin(IVIg) Therapy Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2021-2032) Figure 63. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2021-2032) Figure 64. Global Intravenous Immunoglobulin(IVIg) Therapy Price (US$/Unit) by Type (2021-2032) Figure 65. Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2021-2032) Figure 66. Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2021-2032) Figure 67. Global Intravenous Immunoglobulin(IVIg) Therapy Price (US$/Unit) by Application (2021-2032) Figure 68. Intravenous Immunoglobulin(IVIg) Therapy Value Chain Figure 69. Intravenous Immunoglobulin(IVIg) Therapy Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Intravenous Immunoglobulin(IVIg) Therapy Industry Opportunities and Challenges

Scope & coverage.

Types
  • 5g/100ml
  • 2.5g/50ml
  • 1g/20ml
  • 10g/200ml
  • 1.25g/25ml
  • Others
Applications
  • Autoimmune Disease
  • Immunodeficiency
  • Acute Infection
  • Others
Companies covered
  • TEIJIN LIMITED
  • Baxter
  • Biotest
  • Boya-Bio
  • CNBG
  • CSL Plasma
  • Grifols
  • Kamada
  • Kedrion
  • LFB Group
  • Nanyue Biopharming
  • Octapharma
  • Sinopharm
  • Beijing Tiantan Biological Products
  • Guangdong Shuagnlin Bio-pharmacy
  • Hualan Bio
  • Shanghai RAAS
  • Weiguang Biological
  • Taibang Biologic Group
  • Takeda

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market Size (2021-2032)
  4. 2.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales (2021-2032)
  5. 2.2.3 Global Intravenous Immunoglobulin(IVIg) Therapy Market Average Price (2021-2032)
  6. 2.3 Intravenous Immunoglobulin(IVIg) Therapy by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 5g/100ml
  9. 2.3.3 2.5g/50ml
  10. 2.3.4 1g/20ml
  11. 2.3.5 10g/200ml
  12. 2.3.6 1.25g/25ml
  13. 2.3.7 Others
  14. 2.4 Intravenous Immunoglobulin(IVIg) Therapy by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Autoimmune Disease
  17. 2.4.3 Immunodeficiency
  18. 2.4.4 Acute Infection
  19. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Intravenous Immunoglobulin(IVIg) Therapy Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Intravenous Immunoglobulin(IVIg) Therapy Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Intravenous Immunoglobulin(IVIg) Therapy, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Intravenous Immunoglobulin(IVIg) Therapy, Product Type & Application
  8. 3.8 Global Manufacturers of Intravenous Immunoglobulin(IVIg) Therapy, Established Date
  9. 3.9 Global Intravenous Immunoglobulin(IVIg) Therapy Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 TEIJIN LIMITED
  2. 4.1.1 TEIJIN LIMITED Company Information
  3. 4.1.2 TEIJIN LIMITED Business Overview
  4. 4.1.3 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 TEIJIN LIMITED Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  6. 4.1.5 TEIJIN LIMITED Recent Developments
  7. 4.2 Baxter
  8. 4.2.1 Baxter Company Information
  9. 4.2.2 Baxter Business Overview
  10. 4.2.3 Baxter Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Baxter Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  12. 4.2.5 Baxter Recent Developments
  13. 4.3 Biotest
  14. 4.3.1 Biotest Company Information
  15. 4.3.2 Biotest Business Overview
  16. 4.3.3 Biotest Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Biotest Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  18. 4.3.5 Biotest Recent Developments
  19. 4.4 Boya-Bio
  20. 4.4.1 Boya-Bio Company Information
  21. 4.4.2 Boya-Bio Business Overview
  22. 4.4.3 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Boya-Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  24. 4.4.5 Boya-Bio Recent Developments
  25. 4.5 CNBG
  26. 4.5.1 CNBG Company Information
  27. 4.5.2 CNBG Business Overview
  28. 4.5.3 CNBG Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 CNBG Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  30. 4.5.5 CNBG Recent Developments
  31. 4.6 CSL Plasma
  32. 4.6.1 CSL Plasma Company Information
  33. 4.6.2 CSL Plasma Business Overview
  34. 4.6.3 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 CSL Plasma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  36. 4.6.5 CSL Plasma Recent Developments
  37. 4.7 Grifols
  38. 4.7.1 Grifols Company Information
  39. 4.7.2 Grifols Business Overview
  40. 4.7.3 Grifols Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Grifols Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  42. 4.7.5 Grifols Recent Developments
  43. 4.8 Kamada
  44. 4.8.1 Kamada Company Information
  45. 4.8.2 Kamada Business Overview
  46. 4.8.3 Kamada Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Kamada Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  48. 4.8.5 Kamada Recent Developments
  49. 4.9 Kedrion
  50. 4.9.1 Kedrion Company Information
  51. 4.9.2 Kedrion Business Overview
  52. 4.9.3 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Kedrion Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  54. 4.9.5 Kedrion Recent Developments
  55. 4.10 LFB Group
  56. 4.10.1 LFB Group Company Information
  57. 4.10.2 LFB Group Business Overview
  58. 4.10.3 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 LFB Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  60. 4.10.5 LFB Group Recent Developments
  61. 4.11 Nanyue Biopharming
  62. 4.11.1 Nanyue Biopharming Company Information
  63. 4.11.2 Nanyue Biopharming Business Overview
  64. 4.11.3 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Nanyue Biopharming Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  66. 4.11.5 Nanyue Biopharming Recent Developments
  67. 4.12 Octapharma
  68. 4.12.1 Octapharma Company Information
  69. 4.12.2 Octapharma Business Overview
  70. 4.12.3 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Octapharma Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  72. 4.12.5 Octapharma Recent Developments
  73. 4.13 Sinopharm
  74. 4.13.1 Sinopharm Company Information
  75. 4.13.2 Sinopharm Business Overview
  76. 4.13.3 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sinopharm Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  78. 4.13.5 Sinopharm Recent Developments
  79. 4.14 Beijing Tiantan Biological Products
  80. 4.14.1 Beijing Tiantan Biological Products Company Information
  81. 4.14.2 Beijing Tiantan Biological Products Business Overview
  82. 4.14.3 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Beijing Tiantan Biological Products Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  84. 4.14.5 Beijing Tiantan Biological Products Recent Developments
  85. 4.15 Guangdong Shuagnlin Bio-pharmacy
  86. 4.15.1 Guangdong Shuagnlin Bio-pharmacy Company Information
  87. 4.15.2 Guangdong Shuagnlin Bio-pharmacy Business Overview
  88. 4.15.3 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Guangdong Shuagnlin Bio-pharmacy Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  90. 4.15.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments
  91. 4.16 Hualan Bio
  92. 4.16.1 Hualan Bio Company Information
  93. 4.16.2 Hualan Bio Business Overview
  94. 4.16.3 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Hualan Bio Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  96. 4.16.5 Hualan Bio Recent Developments
  97. 4.17 Shanghai RAAS
  98. 4.17.1 Shanghai RAAS Company Information
  99. 4.17.2 Shanghai RAAS Business Overview
  100. 4.17.3 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Shanghai RAAS Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  102. 4.17.5 Shanghai RAAS Recent Developments
  103. 4.18 Weiguang Biological
  104. 4.18.1 Weiguang Biological Company Information
  105. 4.18.2 Weiguang Biological Business Overview
  106. 4.18.3 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Weiguang Biological Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  108. 4.18.5 Weiguang Biological Recent Developments
  109. 4.19 Taibang Biologic Group
  110. 4.19.1 Taibang Biologic Group Company Information
  111. 4.19.2 Taibang Biologic Group Business Overview
  112. 4.19.3 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Taibang Biologic Group Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  114. 4.19.5 Taibang Biologic Group Recent Developments
  115. 4.20 Takeda
  116. 4.20.1 Takeda Company Information
  117. 4.20.2 Takeda Business Overview
  118. 4.20.3 Takeda Intravenous Immunoglobulin(IVIg) Therapy Sales, Revenue and Gross Margin (2021-2026)
  119. 4.20.4 Takeda Intravenous Immunoglobulin(IVIg) Therapy Product Portfolio
  120. 4.20.5 Takeda Recent Developments
5 Global Intravenous Immunoglobulin(IVIg) Therapy Market Scenario by Region
  1. 5.1 Global Intravenous Immunoglobulin(IVIg) Therapy Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021-2032
  3. 5.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2021-2026
  4. 5.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Region: 2027-2032
  5. 5.3 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region: 2021-2032
  6. 5.3.1 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region: 2021-2026
  7. 5.3.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Region: 2027-2032
  8. 5.4 North America Intravenous Immunoglobulin(IVIg) Therapy Market Facts & Figures by Country
  9. 5.4.1 North America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  11. 5.4.3 North America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Intravenous Immunoglobulin(IVIg) Therapy Market Facts & Figures by Country
  15. 5.5.1 Europe Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  17. 5.5.3 Europe Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Intravenous Immunoglobulin(IVIg) Therapy Market Facts & Figures by Country
  35. 5.7.1 South America Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  37. 5.7.3 South America Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Intravenous Immunoglobulin(IVIg) Therapy Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021-2032)
  2. 6.1.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Type (2021-2032)
  4. 6.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Type (2021-2032)
  5. 6.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Intravenous Immunoglobulin(IVIg) Therapy Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021-2032)
  2. 7.1.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Intravenous Immunoglobulin(IVIg) Therapy Sales Market Share by Application (2021-2032)
  4. 7.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue by Application (2021-2032)
  5. 7.2.1 Global Intravenous Immunoglobulin(IVIg) Therapy Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Intravenous Immunoglobulin(IVIg) Therapy Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Intravenous Immunoglobulin(IVIg) Therapy Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Intravenous Immunoglobulin(IVIg) Therapy Value Chain Analysis
  2. 8.1.1 Intravenous Immunoglobulin(IVIg) Therapy Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Intravenous Immunoglobulin(IVIg) Therapy Production Mode & Process
  5. 8.2 Intravenous Immunoglobulin(IVIg) Therapy Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Intravenous Immunoglobulin(IVIg) Therapy Distributors
  8. 8.2.3 Intravenous Immunoglobulin(IVIg) Therapy Customers
9 Global Intravenous Immunoglobulin(IVIg) Therapy Analyzing Market Dynamics
  1. 9.1 Intravenous Immunoglobulin(IVIg) Therapy Industry Trends
  2. 9.2 Intravenous Immunoglobulin(IVIg) Therapy Industry Drivers
  3. 9.3 Intravenous Immunoglobulin(IVIg) Therapy Industry Opportunities and Challenges
  4. 9.4 Intravenous Immunoglobulin(IVIg) Therapy Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst